Riik: Malta
keel: inglise
Allikas: Malta Medicines Authority
NOMEGESTROL ACETATE
Laboratoire Theramex 6 Avenue Albert II, B.P. 59, 98007 Monaco Cedex, Monaco
G03DB04
NOMEGESTROL ACETATE 5 mg
TABLET
NOMEGESTROL ACETATE 5 mg
POM
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Withdrawn
2006-04-13
Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT LUTENYL ® 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENT : Nomegestrol acetate .................................................................. 5.00 mg EXCIPIENTS : Lactose ....................................................................................... 120.99 mg Cellulose .................................................................................... 54.94 mg Glycerol palmitostearate ............................................................ 3.70 mg Anhydrous colloïdal silica ......................................................... 0.37 mg _For a scored tablet weighing ..................................................... _ _185.00 mg _ 3. PHARMACEUTICAL FORM Scored tablet. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In premenopausal women: menstrual disorders associated with a deficient or absent progesterone secretion, in particular: • Disorders of cycle duration: oligomenorrhoea, polymenorrhoea, spaniomenorrhoea, amenorrhoea (after investigation of the cause) • Functional uterine bleeding: metrorrhagia, menorrhagia, including cases related to fibroma; • Functional signs and symptoms preceding or accompanying periods: essential dysmenorrhoea, premenstrual syndrome, cyclical mastodynia. In postmenopausal women: artificial cycles in combination with an estrogen. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The daily dose is usually 5 mg, i.e. one tablet per day. In premenopausal women: the usual treatment regimen is 10 days per cycle, from the 16 th to the 25 th day inclusive. In postmenopausal women: Lugege kogu dokumenti